Prognostic significance of downregulated expression of programmed cell death 5 in chondrosarcoma
β Scribed by Changbao Chen; Hua Zhou; Lanjun Xu; Xiaoguang Liu; Zhongjun Liu; Dalong Ma; Yingyu Chen; Qingjun Ma
- Publisher
- John Wiley and Sons
- Year
- 2010
- Tongue
- English
- Weight
- 189 KB
- Volume
- 102
- Category
- Article
- ISSN
- 0022-4790
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
Background and Objectives
Programmed Cell Death 5 (PDCD5) is a novel apoptosisβrelated gene and deregulation of PDCD5 is involved in tumorigenicity. This study was designed to investigate the expression level of PDCD5 and to clarify its clinical significance in chondrosarcoma.
Methods
The mRNA and protein levels of PDCD5 in chondrosarcoma and matched corresponding nonβtumor tissues were evaluated by realβtime PCR and Western blot, respectively. The expression of PDCD5 protein was investigated by immunohistochemistry assays in chondrosarcoma, and its association with clinicopathologic factors and overall survival was also analyzed.
Results
The mRNA and protein levels of PDCD5 were significantly decreased in chondrosarcoma compared with corresponding nonβtumor tissues. Low expression of PDCD5 protein was 61.8% (21/34) in chondrosarcomas, as compared 12.5% (1/8) in normal bones, as well as compared 23.5% (4/17) in benign cartilage tumors. PDCD5 expression was correlated with anatomical location and histological grade. The survival rate of patients with lowβPDCD5 tumors was lower than that of patients with highβPDCD5 tumors. Multivariate analysis revealed that the downregulated expression of PDCD5 was an independent prognostic factor for overall survival.
Conclusions
PDCD5 is downregulated in chondrosarcoma and might be an independent prognostic factor for overall survival of chondrosarcoma patients. J. Surg. Oncol. 2010;102:838β843. Β© 2010 WileyβLiss, Inc.
π SIMILAR VOLUMES
## Background and objectives: It is generally accepted that the overexpression of p53 protein is associated with poor prognosis in breast, colorectal, and other types of cancer. however, the prognostic significance of p53 aberrations in esophageal squamous cell carcinoma has yet to be determined. w